Care of inflammatory bowel disease patients in remission

Gastroenterology Report

Volumn 4, Issue 4, 2016, Pages 261-271

  Subramanian, Charumathi Raghu ^b   Triadafilopoulos, George ^a  

^a STANFORD UNIVERSITY   (United States)

^b GUTHRIE RESEARCH INSTITUTE   (United States)

Author keywords

Inflammatory bowel disease; Long term care; Remission

Indexed keywords

EID: 85028320324     PISSN: None     EISSN: 20520034     Source Type: Journal    
DOI: 10.1093/gastro/gow032     Document Type: Review

References (131)

1. Danese S, Sans M and Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004;3:394-400.
2. Cohen RD, Yu AP, Wu EQ, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010;31:693-707.
3. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907-13.
4. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996;334:841-8.
5. Øresland T nd2 Faerden AE. Surgery in the age of biological treatment. Scand J Gastroenterol 2015;50:121-7.
6. van der Have M, Fidder HH, Leenders M, et al. COIN study group; Dutch Initiative on Crohn and Colitis. Self-reported disability in patients with inflammatory bowel disease largely determined by disease activity and illness perceptions. Inflamm Bowel Dis 2015;21:369-77.
7. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53.
8. Schroeder KW, Tremaine WJ and Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
9. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976;70:439-44.
10. Harvey R and Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980;8:514.
11. Selby L, Hoellein A and Wilson JF. Are primary care providers uncomfortable providing routine preventive care for inflammatory bowel disease patients? Dig Dis Sci 2011;56:819-24.
12. Bennett AL, Munkholm P and Andrews JM. Tools for primary care management of inflammatory bowel disease: do they exist? World J Gastroenterol 2015;21:4457-65.
13. Kappelman MD, Palmer L, Boyle BM, et al. Quality of care in inflammatory bowel disease: a review and discussion. Inflamm Bowel Dis 2010;16:125-133.
14. Knowles SR and Antonina MW. Utilization and efficacy of internet-based eHealth technology in gastroenterology: a systematic review. Scand J Gastroenterol 2014;49:387-408.
15. Sonnenberg A. Disability and need for rehabilitation among patients with inflammatory bowel disease. Digestion 1992; 51:168-78.
16. Bernstein CN, Kraut A, Blanchard JF, et al. The relationship between inflammatory bowel disease and socioeconomic variables. Am J Gastroenterol 2001;96:2117-25.
17. Marri SR and Buchman AL. The education and employment status of patients with inflammatory bowel diseases. Inflamm Bowel Dis 2005;11:171-7.
18. Netjes JE and Rijken M. Labor participation among patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19:81-91.
19. Siebert U, Wurm J, Gothe RM, et al. Predictors of temporary and permanent work disability in patients with inflammatory bowel disease: results of the Swiss Inflammatory Bowel Disease Cohort Study. Inflamm Bowel Dis 2013;19:847-55.
20. Russel MG, Ryan BM, Dagnelie PC, et al. Insurance problems among inflammatory bowel disease patients: results of a Dutch population based study. Gut 2003;52:358-62.
21. Hilsden RJ, Verhoef MJ, Rasmussen H, et al. Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:655-62.
22. Lindberg A, Fossum B, Karlen P, et al. Experiences of complementary and alternative medicine in patients with inflammatory bowel disease - a qualitative study. BMC Complement Altern Med 2014;14:407.
23. Benchimol EI, Seow CH, Steinhart AH, et al. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2008;(2):CD006792.
24. Reddy SI, Friedman S, Telford JJ, et al. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol 2005;100:1357-61.
25. Herrinton LJ, Liu L, Fireman B, et al. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology 2009;137: 502-11.
26. Tan VP, Chung A, Yan BP, et al. Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol 2013;28:1095-113.
27. Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010;139:779-87,e1.
28. Wallaert JB, De Martino RB, Marsicovetere PS, et al. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum 2012;55:1138-44.
29. Papa A, Gerardi V, Marzo M, et al. Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment. World J Gastroenterol 2014;20:3173-9.
30. van Leuven SI, Hezemans R, Levels JH, et al. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn’s disease. J Lipid Res 2007;48:2640-6.
31. Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death-a Danish nationwide cohort study. PLoS One 2013;8:e56944.
32. Fumery M, Xiaocang C, Dauchet L, et al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis 2014;8:469-79.
33. Osterman MT, Yang YX, Brensinger C, et al. No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn’s disease. Clin Gastroenterol Hepatol 2011;9: 875-80.
34. Ruisi P, Makaryus JN, Ruisi M, et al. Inflammatory bowel disease as a risk factor for premature coronary artery disease. J Clin Med Res 2015;7:257-61.
35. Andersen NN, Rungoe C, Andersson M, et al. Tumor necrosis factor alpha antagonists and cardiovascular disease in Inflammatory bowel disease. In: Programs and Abstracts of the Eighth Congress of ECCO, Vienna, Austria, 2013. Abstract 19. European Crohn’s and Colitis Organisation, Vienna, Austria.
36. Zanoli L, Rastelli S, Inserra G, et al. Increased arterial stiffness in inflammatory bowel diseases is dependent upon inflammation and reduced by immunomodulatory drugs. Atherosclerosis 2014;234:346-51.
37. Karaahmet F, Basar O, Coban S, et al Dyslipidemia and inflammation in patients with inflammatory bowel disease. Dig Dis Sci 2013;58:1806-7.
38. Crockett SD, Hansen RA, Stürmer T, et al. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis 2012;18:1048-56.
39. Zella GC, Hait EJ, Glavan T, et al. Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis. Inflamm Bowel Dis 2011; 17:1092-100.
40. Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology 2010; 139:1816-9.
41. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011;472:57-63.
42. Ueno A, Jijon H, Traves S, et al. Opposing effects of smoking in ulcerative colitis and Crohn’s disease may be explained by differential effects on dendritic cells. Inflamm Bowel Dis 2014;20:800-10.
43. Lunney PC, Kariyawasam VC, Wang RR, et al. Smoking prevalence and its influence on disease course and surgery in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther 2015;42:61-70.
44. Ott C, Takses A, Obermeier F, et al. Smoking increases the risk of extraintestinal manifestations in Crohn’s disease. World J Gastroenterol 2014;34:12269-76.
45. Gisbert JP, Marın AC and Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther 2015;42:391-405.
46. Cosnes J, Beaugerie L, Carbonnel F, et al. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology 2001;120:1093-9.
47. Bastida G and Beltran B. Ulcerative colitis in smokers, nonsmokers and ex-smokers. World J Gastroenterol 2011;22: 2740-7.
48. Beaugerie L, Massot N, Carbonnel F, et al. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol 2001;96:2113-6.
49. Loftus EV, Sandborn WJ, Tremaine WJ, et al. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 1996;110:1496-502.
50. Roth LS, Chande N, Ponich T, et al. Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario. World J Gastroenterol 2010;16:232-6.
51. Saadoune N, Peyrin-Biroulet L, Baumann C, et al. Beliefs and behaviour about smoking among inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2015;27:797-803.
52. Ducharme-Bénard S, Côté-Daigneault J, Lemoyne M, et al. Patients with inflammatory bowel disease are unaware of the impact of smoking on their disease. J Clin Gastroenterol, 2016;50:490-7.
53. Biedermann L, Fournier N, Misselwitz B, et al. High rates of smoking especially in female Crohn’s disease patients and low use of supportive measures to achieve smoking cessation-data from the Swiss IBD Cohort Study. J Crohns Colitis 2015;9:819-29.
54. Marın L, Mañosa M, Garcia-Planella E, et al. Sexual function and patients’ perceptions in inflammatory bowel disease: a case-control survey. J Gastroenterol 2013;48:713-20.
55. Moleski SM and Choudhary C. Special considerations for women with IBD. Gastroenterol Clin North Am 2011;40:387-98, viii-ix.
56. Feagins L And Kane SV. Sexual and reproductive issues for men with inflammatory bowel disease. Am J Gastroenterol 2009;104:768-73.
57. Wang JY, Hart SL, Wilkowski KS, et al. Gender-specific differences in pelvic organ function after proctectomy for inflammatory bowel disease. Dis Colon Rectum 2011;54:66-76.
58. Ørding OK, Juul S, Berndtsson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002;122:15-9.
59. Arora Z and Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) 2015;3:103-9.
60. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012;107:1409-22 .
61. Nanau RM, Cohen LE and Neuman MG. Risk of infections of biological therapies with accent on inflammatory bowel disease. J Pharm Pharm Sci 2014;17:485-531.
62. Tsai SY, Yang TY, Lin CL, et al. Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population-based cohort study. Int J Clin Pract 2015;69:228-34.
63. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55:1-33; quiz CE1-4.
64. Agarwal N, Ollington K, Kaneshiro M, et al. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine 2012;30:1413-24.
65. Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis 2012;18:261-8.
66. Rahier JF, Papay P, Salleron J, et al. H1N1 Vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011;60:456-62.
67. Lodhia N. The appropriate use of vaccines in patients with inflammatory bowel disease. J Clin Gastroenterol 2014;48: 395-401.
68. Reich JS, Miller HL, Wasan SK, et al. Influenza and pneumococcal vaccination rates in patients with inflammatory bowel disease. Gastroenterol Hepatol 2015;11:396-401.
69. Abdallah J, Anna K, Hassan T, et al. 959 Vaccination Outcomes in Inflammatory Bowel Disease. Gastroenterology 2014;146: S-170.
70. Cossio-Gil Y, Martınez-Gomez X, Campins-Martı M, et al. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination. J Gastroenterol Hepatol 2015;30:92-8.
71. Gisbert JP, Menchén L, Garcıa-Sanchez V, et al. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:1379-85.
72. Subramaniam K, D’Rozario J and Pavli P. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol 2013;28: 24-30.
73. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.
74. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 2015;13:847-58.e4; quiz e48-50.
75. Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology 2013;145:1007-15.e3.
76. Mantzaris GJ. Previous cancer and/or lymphoma in patients with refractory IBD-con: anti-TNF or conventional immunosuppressive treatment. Dig Dis 2014;32 Suppl 1: 122-7.
77. Kalman RS, Hartshorn K and Farraye FA. Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD. Inflamm Bowel Dis 2015; 21:428-35.
78. Tabibian A, Tabibian JH, Beckman LJ, et al. Predictors of health-related quality of life and adherence in Crohn’s disease and ulcerative colitis: implications for clinical management. Dig Dis Sci 2015;60:1366-74.
79. Keeton RL, Mikocka-Walus A and Andrews JM. Concerns and worries in people living with inflammatory bowel disease (IBD): a mixed methods study. J Psychosom Res 2015; 78:573-78.
80. Hauser € W, Moser G, Klose P, et al. Psychosocial issues in evidence-based guidelines on inflammatory bowel diseases: a review. World J Gastroenterol 2014;13:3663-71.
81. Goodhand JR, Greig FI, Koodun Y, et al. Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study. Inflamm Bowel Dis 2012;18:1232-39.
82. Iskandar HN, Cassell B, Kanuri N, et al. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol 2014;48:423-29.
83. Horst S, Chao A, Rosen M, et al. Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease. Dig Dis Sci 2015; 60:465-70.
84. McCombie AM, Mulder RT and Gearry RB. Psychotherapy for inflammatory bowel disease: a review and update. J Crohns Colitis 2013;7:935-49.
85. Knowles SR, Gass C and Macrae F. Illness perceptions in IBD influence psychological status, sexual health and satisfaction, body image and relational functioning: A preliminary exploration using Structural Equation Modeling. J Crohns Colitis 2013;7:e344-50.
86. O’Leary F and Samman S. Vitamin B12 in health and disease. Nutrients 2010;2:299-316.
87. Attree EA, Dancey CP, Keeling D, et al. Cognitive function in people with chronic illness: inflammatory bowel disease and irritable bowel syndrome. Appl Neuropsychol 2003;10: 96-104.
88. Berrill JW, Gallacher J, Hood K, et al. An observational study of cognitive function in patients with irritable bowel syndrome and inflammatory bowel disease. Neurogastroenterol Motil 2013;25:918-e704.
89. Montalto M, Gallo A, Santoro L, et al. Role of fecal calprotectin in gastrointestinal disorders. Eur Rev Med Pharmacol Sci 2013;17:1569-82.
90. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
91. Costantino G, Furfaro F, Belvedere A, et al. Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up. J Crohns Colitis 2012;6:588-96.
92. Wallace TM and Veldhuyzen van Zanten SJ. Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists. Can J Gastroenterol 2001;15: 21-8.
93. Setshedi M, Epstein D, Winter TA, et al. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2012;27:385-9.
94. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for non-melanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-28.
95. Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis 2014;8:31-44.
96. De Luca JF, Severino R, Lee YS, et al. Dermatologist and gastroenterologist awareness of the potential of immuno-suppressants used to treat inflammatory bowel disease to cause non-melanoma skin cancer. Int J Dermatol 2013;52:955-9.
97. Goodhand JR, Kamperidis N, Nguyen H, et al. Rampton. Application of the WHO fracture risk assessment tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis. Aliment Pharmacol Ther 2011;33:551-8.
98. Krajcovicova A, Hlavaty T, Killinger Z, et al. Combination therapy with an immunomodulator and anti-TNFa agent improves bone mineral density in IBD patients. J Crohns Colitis 2014;8:1693-701.
99. Miznerova E, Hlavaty T, Koller T, et al. The prevalence and risk factors for osteoporosis in patients with inflammatory bowel disease. Bratisl Lek Listy 2013;114:439-45.
100. Tsai MS, Lin CL, Tu YK, et al. Risks and predictors of osteoporosis in patients with inflammatory bowel diseases in an Asian population: a nationwide population-based cohort study. Int J Clinical Pract 2015;69:235-41.
101. Bernstein CN, Leslie WD and Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003;124:795-841.
102. Adriani A, Pantaleoni S, Luchino M, et al. Osteopenia and osteoporosis in patients with new diagnosis of inflammatory bowel disease. Panminerva Med 2014;56:145-9.
103. Atreja A, Aggarwal A, Licata AA, et al. Low body mass index can identify majority of osteoporotic inflammatory bowel disease patients missed by current guidelines. Scientific World Journal 2012;2012:807438.
104. Lim H, Kim HJ, Hong SJ, et al. Nutrient intake and bone mineral density by nutritional status in patients with inflammatory bowel disease. J Bone Metabol 2014;21:195-203.
105. Melek J and Sakuraba A. Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review. Clin Gastroenterol Hepatol 2014;12:32-44.
106. Kaplan GG, Hubbard J, Panaccione R, et al. Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg 2011;146:959-64.
107. Vagianos K, Clara I, Carr R, et al. What Are Adults With Inflammatory Bowel Disease (IBD) Eating? A Closer Look at the Dietary Habits of a Population-Based Canadian IBD Cohort. JPEN J Parenter Enteral Nutr 2016;40:405-11.
108. Filippi J, Al-Jaouni R, Wiroth J, et al. Nutritional deficiencies in patients with Crohn’s disease in remission. Inflamm Bowel Dis 2006;12:185-91.
109. Rogler G and Vavricka S. Anemia in inflammatory bowel disease: an under-estimated problem? Front Med 2015;1:58.
110. Hebuterne X, Filippi J and Schneider SM. Nutrition in adult patients with inflammatory bowel disease. Curr Drug Targets 2014;15:1030-8.
111. Torki M, Gholamrezaei A, Mirbagher L, et al. Vitamin D deficiency associated with disease activity in patients with inflammatory bowel diseases. Dig Dis Sci 2015;60: 3085-91.
112. Hlavaty T, Krajcovicova A, Koller T, et al. Higher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseases. World J Gastroenterol 2014;20:15787-96.
113. Hlavaty T, Krajcovicova A and Payer J. Vitamin D therapy in inflammatory bowel diseases: who, in what form, and how much? J Crohns Colitis 2015;9:198-209.
114. Triantafillidis JK, Vagianos C and Papalois AE. The role of enteral nutrition in patients with inflammatory bowel disease: current aspects. Biomed Res Int 2015;2015:197167.
115. Kaser A, Zeissig S and Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010;28:573-621.
116. Celiberto LS, Bedani R, Rossi EA, et al. Probiotics: the scientific evidence in the context of inflammatory bowel disease. Crit Rev Food Sci Nutr 2015 May 21. [Epub ahead of print]
117. Fedorak RN and Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:286-99.
118. Geier MS, Butler RN, and Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol 2007;115:1-11.
119. Gionchetti P, Calafiore A, Pratico C, et al. Randomized controlled trials in pouchitis. Rev Recent Clin Trials 2012;7:303-6.
120. Gionchetti P, Calabrese C, Lauri A, et al. The therapeutic potential of antibiotics and probiotics in the treatment of pouchitis. Expert Rev Gastroenterol Hepatol 2015;9: 1175-81.
121. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004:53:108-14.
122. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015;149:102-9.e6.
123. Shabbir J and Britton DC. Stoma complications: a literature overview. Colorectal Dis 2010;12:958-64.
124. Caricato M, Ausania F, Ripetti V, et al. Retrospective analysis of long-term defunctioning stoma complications after colorectal surgery. Colorectal Dis 2007;9:559-61.
125. Robertson I, Leung E, Hughes D, et al. Prospective analysis of stoma-related complications. Colorectal Dis 2005;7: 279-85.
126. Bass EM, Del Pino A, Tan A, et al. Does preoperative stoma marking and education by the enterostomal therapist affect outcome? Dis Colon Rectum 1997;40:440-2.
127. Patel F, Fitzmaurice S, Duong C, et al. Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. Acta Derm Venereol 2015;95:525-31.
128. Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1982-92.
129. Rossi RE, Conte D and Massironi S. Primary sclerosing cholangitis associated with inflammatory bowel disease: an update. Eur J Gastroenterol Hepatol 2016;28:123-31.
130. Navaneethan U, Venkatesh PG, Jegadeesan R, et al. Comparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn’s disease. Gastroenterol Rep (Oxf) 2016;4:43-9.
131. Cairns SR, Scholefield JH, Steele RJ, et al; British Society of Gastroenterology; Association of Coloproctology for Great Britain and Ireland. Guidelines for colorectal cancer screening and surveillance in moderate and high-risk groups. Gut 2010;59:666-89.